Zobrazeno 41 - 50
of 63
pro vyhledávání: ''
Publikováno v:
Cancer Prevention Research. 8:B23-B23
Lung cancer is the leading cause of cancer-related mortality worldwide, and 85% of lung cancers are associated with tobacco use. Activating mutations in K-ras have been identified in ~25% of lung adenocarcinomas and are found predominantly in smokers
Publikováno v:
Cancer Prevention Research. 6:PR03-PR03
Lung cancer remains the leading cause of cancer death in the United States and chemoprevention offers an appealing area of investigation in the face of limited therapeutic success. We recently demonstrated improvement in endobronchial histology in fo
Publikováno v:
Cancer Prevention Research. 6:A03-A03
The cells within the mammary gland that are altered by tamoxifen chemoprevention and correlate with abrogation of tumorigenesis are unknown. We have documented that a 60 day tamoxifen chemopreventive regimen reduces tumor incidence in NRL-TGFalpha an
Autor:
Steven M. Dubinett, Elvira L. Liclican, Daniel Brass, Marc E. Lenburg, Kostyantyn Krysan, Avrum Spira, Stacy J. Park, Tonya C. Walser, Catalina Perdomo, Paul P. Pagano
Publikováno v:
Cancer Prevention Research. 6:C58-C58
Lung cancer is the leading cause of cancer deaths in the United States. Despite a strong correlation between cigarette smoking and the onset of lung cancer, the prevalence of smoking still remains high. Significant reduction or elimination of the use
Autor:
Ethan Dmitrovsky
Publikováno v:
Cancer Prevention Research. 6:ED05-03
This session will present on the use of retinoid X receptor (RXR) agonists (rexinoids) for cancer prevention. Several areas will be highlighted. Using lung cancer as a model, both preclinical and clinical evidence for use of RXR-selective ligands in
Autor:
Wen-Pin Chen, Eva Szabo, Rachel Gonzalez, Luz Rodriguez, Jason A. Zell, Daniel L. Gillen, Vanessa Wong, Robert J. Carroll, Richard V. Benya, Asmita Bhattacharya, Frank L. Meyskens, Timothy R. Morgan, Jinah Chung, Steven M. Lipkin
Publikováno v:
Cancer Prevention Research. 6:CN07-01
Colorectal cancer (CRC) progresses through multiple distinct stages that are potentially amenable to chemopreventative intervention. Epidermal Growth Factor Receptor (EGFR) inhibitors can shrink advanced tumors including CRC. There is significant evi
Publikováno v:
Cancer Prevention Research. 5:B110-B110
Cyclooxygenase [COX] inhibitors [piroxicam, celecoxib, naproxen, and NO-naproxen] are potent inhibitors of oral carcinogenesis induced in rats by 4-nitroquinoline-1-oxide [NQO]. By contrast, a model 5-lipoxygenase [LOX] inhibitor [zileuton] has no ch
Publikováno v:
Cancer Prevention Research. 5:A61-A61
A major challenge in cancer therapy is to develop drugs that kill tumor cells without being toxic to normal cells. More than 15 years ago, sulindac and related compounds were shown to have anti-tumor activity that did not appear to be related to suli
Autor:
Wei Zhang, Zhu Bing, Ashraf Abadi, Yaguang Xi, Xi Chen, Kevin S. Lee, Evrim Gurpinar, Maya A. Brownby, Alexandra Fajardo, Heather N. Tinsely, Sara Sigler, Gary A. Piazza, Adam B. Keeton, Nan Li, William E. Grizzle, Veronica Ramirez, Claire Cawthon, Gary D. Bernard
Publikováno v:
Cancer Prevention Research. 5:B59-B59
Nonsteroidal anti-inflammatory drugs (NSAIDs) can significantly reduce the incidence and risk of death from multiple cancers, but their long-term use for chemoprevention is not recommended because of potentially fatal toxicities resulting from cycloo
Autor:
Melissa L. Bondy, Katherine S. Hale, Kim Anh Do, Aysegul A. Sahin, Abenaa M. Brewster, Patricia A. Thompson, Gordon B. Mills, Caimiao Wei
Publikováno v:
Cancer Prevention Research. 5:B84-B84
Background: Gene mutations in the PI3K pathway in breast tumors are associated with resistance to tamoxifen and poorer prognosis. Differences in host susceptibility to developing breast cancers with PI3K pathway mutations may explain the heterogeneit